JP2011505381A5 - - Google Patents

Download PDF

Info

Publication number
JP2011505381A5
JP2011505381A5 JP2010536228A JP2010536228A JP2011505381A5 JP 2011505381 A5 JP2011505381 A5 JP 2011505381A5 JP 2010536228 A JP2010536228 A JP 2010536228A JP 2010536228 A JP2010536228 A JP 2010536228A JP 2011505381 A5 JP2011505381 A5 JP 2011505381A5
Authority
JP
Japan
Prior art keywords
region
seq
antibody
segment
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010536228A
Other languages
English (en)
Japanese (ja)
Other versions
JP5781765B2 (ja
JP2011505381A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/085196 external-priority patent/WO2009073631A2/en
Publication of JP2011505381A publication Critical patent/JP2011505381A/ja
Publication of JP2011505381A5 publication Critical patent/JP2011505381A5/ja
Application granted granted Critical
Publication of JP5781765B2 publication Critical patent/JP5781765B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010536228A 2007-11-30 2008-12-01 シュードモナス・エルギノーサ（ＰｓｅｕｄｏｍｏｎａｓＡｅｒｕｇｉｎｏｓａ）のＰｃｒＶ抗原に対する抗体 Expired - Fee Related JP5781765B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99167907P 2007-11-30 2007-11-30
US60/991,679 2007-11-30
PCT/US2008/085196 WO2009073631A2 (en) 2007-11-30 2008-12-01 Antibodies to the pcrv antigen of pseudomonas aeruginosa

Publications (3)

Publication Number Publication Date
JP2011505381A JP2011505381A (ja) 2011-02-24
JP2011505381A5 true JP2011505381A5 (enExample) 2012-01-26
JP5781765B2 JP5781765B2 (ja) 2015-09-24

Family

ID=40527381

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010536228A Expired - Fee Related JP5781765B2 (ja) 2007-11-30 2008-12-01 シュードモナス・エルギノーサ（ＰｓｅｕｄｏｍｏｎａｓＡｅｒｕｇｉｎｏｓａ）のＰｃｒＶ抗原に対する抗体

Country Status (15)

Country Link
US (3) US8044181B2 (enExample)
EP (1) EP2220117A2 (enExample)
JP (1) JP5781765B2 (enExample)
KR (1) KR20100097719A (enExample)
CN (1) CN101910197B (enExample)
AU (1) AU2008333985B2 (enExample)
BR (1) BRPI0819598A2 (enExample)
CA (1) CA2706732A1 (enExample)
EA (1) EA201000903A1 (enExample)
IL (1) IL206036A0 (enExample)
MX (1) MX2010005871A (enExample)
NZ (1) NZ586357A (enExample)
SG (1) SG186017A1 (enExample)
WO (1) WO2009073631A2 (enExample)
ZA (1) ZA201003852B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
EP2412816B1 (en) 2004-07-26 2014-12-03 Pfenex Inc. Process for improved protein expression by strain engineering
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
EP2615172A1 (en) * 2007-04-27 2013-07-17 Pfenex Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
WO2009088032A1 (ja) 2008-01-10 2009-07-16 Shionogi & Co., Ltd. ＰｃｒＶに対する抗体
CA2751433A1 (en) * 2009-02-04 2010-08-12 Kalobios Pharmaceuticals, Inc. Combination antibiotic and antibody therapy for the treatment of pseudomonas aeruginosa infection
CN102341496B (zh) * 2009-03-11 2014-07-02 盐野义制药株式会社 具有抗绿脓杆菌作用的人源化PcrV抗体
JP2013515079A (ja) * 2009-12-22 2013-05-02 カロバイオス ファーマシューティカルズ インコーポレイティッド 低レベルの病原性シュードモナス・エルギノーサ（Ｐｓｅｕｄｏｍｏｎａｓａｅｒｕｇｉｎｏｓａ）感染症を有する患者のスタフィロコッカス（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ）感染症を治療する方法
US8512950B2 (en) 2010-07-21 2013-08-20 Saint Louis University Biolayer interferometry measurement of biological targets
CA2838211C (en) 2011-06-10 2023-08-01 Medimmmune Limited Anti-pseudomonas psl binding molecules and uses thereof
HUE050985T2 (hu) 2011-11-07 2021-01-28 Medimmune Ltd Pseudomonas PSL és PCRV elleni kötõmolekulát alkalmazó kombinációs terápiák
EP2820043B1 (en) 2012-03-02 2020-01-15 Ablynx N.V. Biparatopic pseudomonas aeruginosa pcrv binding single variable domain antibodies
KR20150082367A (ko) * 2012-11-06 2015-07-15 메디뮨 엘엘씨 항슈도모나스 ｐｓｌ 및 ｐｃｒｖ 결합 분자를 이용한 병용 요법
RU2759949C2 (ru) * 2015-05-01 2021-11-19 Инхибркс, Инк. Молекулы, нацеленные на систему секреции типа iii
EP3322734B1 (en) 2015-07-16 2020-09-09 Inhibrx, Inc. Multivalent and multispecific dr5-binding fusion proteins
AU2017261374B2 (en) * 2016-05-05 2024-06-20 Inovio Pharmaceuticals, Inc. DNA antibody constructs for use against pseudomonas aeruginosa
KR20210041586A (ko) * 2018-08-01 2021-04-15 세파론, 인코포레이티드 항-cxcr2 항체 및 이의 용도
CN113966343A (zh) * 2019-06-11 2022-01-21 瑞泽恩制药公司 结合PcrV的抗PcrV抗体、包含抗PcrV抗体的组合物及其使用方法
CN118620074A (zh) * 2020-06-01 2024-09-10 北京三诺佳邑生物技术有限责任公司 特异性识别假单胞菌pcrv的抗体及其用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US134098A (en) * 1872-12-17 Improvement in gage-cocks
US225552A (en) * 1880-03-16 Disintegrating-mill
US108565A (en) * 1870-10-25 Improvement in snow-plows
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5219998A (en) * 1990-06-04 1993-06-15 Levin Robert H Yeast-derived epidermal growth factor
GB9012995D0 (en) 1990-06-11 1990-08-01 Celltech Ltd Multivalent antigen-binding proteins
CA2267620A1 (en) 1996-07-16 1998-01-22 Andreas Pluckthun Immunoglobulin superfamily domains and fragments with increased solubility
US7141393B2 (en) 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
WO2000033872A2 (en) 1998-11-25 2000-06-15 Mcw Research Foundation, Inc. Method of and compositions for immunization with the pseudomonas v antigen
DE19918418C1 (de) * 1999-04-23 2000-10-19 Siegfried Mueller Pflanzvorrichtung mit Halterung
WO2001064749A2 (en) 2000-02-28 2001-09-07 Idec Pharmaceuticals Corporation Method for preparing anti-mif antibodies
WO2002064161A2 (en) * 2001-01-26 2002-08-22 Mcw Research Foundation, Inc. Method and compositions for immunization with the pseudomonas v antigen
CA2374027A1 (en) 2001-03-13 2002-09-13 The Minister Of National Defence Cloning, expression, sequencing, and functional enhancement of monoclonal scfv antibody against venezuelan equine encephalitis virus(vee)
ES2338105T3 (es) * 2003-05-14 2010-05-04 Kenta Biotech Ag Anticuerpo monoclonal humano especifico para lipopolisacaridos (lps) de serotipo iats 06 pseudomonas aeruginosa.
EP2990053A1 (en) 2004-01-20 2016-03-02 KaloBios Pharmaceuticals, Inc. Antibody specificity transfer using minimal essential binding determinants
PL2343380T3 (pl) 2004-11-16 2020-03-31 Humanigen, Inc. Wymiana kasety dla regionu zmiennego immunoglobuliny
AU2006249087B2 (en) 2005-05-20 2012-05-17 Lonza Biologics Plc High-level expression of recombinant antibody in a mammalian host cell
EP1726650A1 (en) 2005-05-27 2006-11-29 Universitätsklinikum Freiburg Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
KR20080031383A (ko) 2005-07-05 2008-04-08 베이커 메디컬 리서치 인스티튜트 항응고제 및 그의 용도
JP2009531295A (ja) 2006-02-22 2009-09-03 ユニバーシティ オブ チューリッヒ 自己免疫疾患又は脱髄疾患を処置するための方法
ATE495195T1 (de) 2006-06-02 2011-01-15 Aveo Pharmaceuticals Inc Hepatocytenwachstumsfaktor-(hgf-)bindungsprotei e
CN101573383B (zh) 2006-06-21 2015-05-13 肿瘤疗法科学股份有限公司 靶向肿瘤的针对卷曲同源物10的单克隆抗体及其用途

Similar Documents

Publication Publication Date Title
JP5781765B2 (ja) シュードモナス・エルギノーサ（ＰｓｅｕｄｏｍｏｎａｓＡｅｒｕｇｉｎｏｓａ）のＰｃｒＶ抗原に対する抗体
US12428473B2 (en) Combination therapies using anti-pseudomonas PSL and PCRV binding molecules
JP2011505381A5 (enExample)
US8653242B2 (en) Therapeutic antibodies against flagellated Pseudomonas aeruginosa
US20150284450A1 (en) Combination therapies using anti-pseudomonas psl and pcrv binding molecules
US20100272736A1 (en) Combination antibiotic and antibody therapy for the treatment of pseudomonas aeruginosa infection
HK1201453B (en) Combination therapies using anti- pseudomonas psl and pcrv binding molecules
NZ722379B2 (en) Combination therapies using anti-pseudomonas psl and pcrv binding molecules